Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial

Angela Alistar, Bonny B. Morris, Rodwige Desnoyer, Heidi D. Klepin, Keyanoosh Hosseinzadeh, Clancy Clark, Amy Cameron, John Leyendecker, Ralph D'Agostino, Umit Topaloglu, Lakmal W. Boteju, Asela R. Boteju, Rob Shorr, Zuzana Zachar, Paul M. Bingham, Tamjeed Ahmed, Sandrine Crane, Riddhishkumar Shah, John J. Migliano, Timothy S. PardeeLance Miller, Gregory Hawkins, Guangxu Jin, Wei Zhang, Boris Pasche

Research output: Contribution to journalArticlepeer-review

99 Scopus citations

Fingerprint

Dive into the research topics of 'Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences